Key Takeaways
- ExxonMobil (XOM) has significantly raised its 2030 corporate plan, now targeting $25 billion in earnings growth and $145 billion in cumulative surplus cash flow through 2030, alongside an increased structural cost savings plan of $20 billion.
- AutoZone (AZO) reported a mixed first quarter, with sales of $4.63 billion surpassing analyst estimates, but diluted EPS of $31.04 and net income of $530.82 million falling short of expectations. The company did, however, achieve a robust 22% like-for-like sales growth.
- Commodity trading giant Trafigura announced 2025 profits topping $2.6 billion after a strong year in metals and oil, yet its share buybacks for the year outstripped these profits at $2.9 billion.
- CVS Health (CVS) updated its full-year guidance, projecting revenue of at least $400 billion and adjusted EPS between $6.60 and $6.70, while still anticipating a GAAP loss per share in the range of $0.22 to $0.32.
- Pfizer (PFE) entered an exclusive collaboration with Yaopharma for a GLP-1 receptor agonist, involving an upfront payment of $150 million and potential milestone payments of up to $1.935 billion.
Corporate Outlooks and Earnings Highlights
ExxonMobil (XOM) has unveiled an ambitious updated corporate plan through 2030, projecting substantial growth and increased shareholder value. The energy major now expects to achieve $25 billion in earnings growth and $35 billion in cash flow growth by 2030, based on constant prices and margins. This plan includes increasing its structural cost savings target to $20 billion compared to 2019 levels. Furthermore, ExxonMobil anticipates generating approximately $145 billion in cumulative surplus cash flow through 2030. The company also aims to boost its upstream production to 5.4 million oil-equivalent barrels per day by 2030, with over 60% sourced from advantaged assets.
AutoZone (AZO) reported its first-quarter fiscal 2026 results, presenting a mixed financial picture. The automotive parts retailer posted Q1 sales of $4.628 billion, exceeding the IBES estimate of $4.569 billion. However, its Q1 diluted earnings per share (EPS) of $31.04 fell short of the IBES estimate of $37.10. Net income for the quarter was $530.82 million, below the $622 million estimate, and operating profit of $784.20 million also missed the $912.8 million IBES estimate. Despite these misses, AutoZone demonstrated strong operational performance with a 22% increase in Q1 like-for-like sales.
Commodity trading powerhouse Trafigura announced robust financial performance for 2025, with profits from its metals and oil divisions pushing total profits to $2.6 billion. However, the company's share buybacks for the year totaled $2.9 billion, outstripping its annual profits. This dynamic highlights the significant capital demands of its employee ownership structure and ongoing management of share repurchases.
CVS Health (CVS) has provided an updated outlook for its fiscal year, raising its revenue forecast to at least $400 billion, up from a previous projection of at least $397.3 billion. The healthcare giant also increased its adjusted EPS guidance to a range of $6.60 to $6.70, an improvement from the prior $6.55 to $6.65 range. Despite these positive adjustments, CVS still anticipates a GAAP loss per share between $0.22 and $0.32 for the full year. The company maintains its full-year cash flow from operations guidance at $7.5 billion to $8 billion.
In the pharmaceutical sector, Pfizer (PFE) has entered a significant exclusive collaboration and license agreement with Yaopharma. The partnership focuses on the development of YP05002, a small molecule GLP-1 receptor agonist currently in Phase 1 trials for chronic weight management. Under the terms of the agreement, Yaopharma will receive an upfront payment of $150 million and is eligible for up to $1.935 billion in development, regulatory, and commercial milestone payments, along with tiered royalties on sales if the drug is approved.
Other Noteworthy Developments
A report commissioned by the U.K. Government has revealed that COVID-19 fraud and error cost taxpayers an estimated £10.9 billion. The findings highlight the financial impact of widespread exploitation of hastily implemented pandemic support schemes.
On the political front, Donald Trump has indicated that support for immediately cutting interest rates would be a "litmus test" for his nominee to lead the Federal Reserve. This stance underscores his continued focus on monetary policy and its potential impact on the economy. Trump also suggested he might implement tariff changes to lower some prices.
Finally, Citigroup has raised its target price for Apple Inc. (AAPL) shares to $330 from $315, while maintaining a "Buy" rating on the stock. This analyst upgrade reflects continued confidence in the technology giant's performance.
Ed Liston is a senior contributing editor at TheStockMarketWatch.com. An active market watcher and investor, Ed guides an independent team of experienced analysts and writes for multiple stock trader publications.